Alliance for Pandemic Preparedness

March 12, 2021

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials

Category:

Topic:

Keywords (Tags):

  • [Press release, not peer-reviewed] A Phase 3 trial of the Novavax vaccine (NVX‑CoV2373) in the UK indicated an efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain. The company also announced final results of its Phase 2b trial conducted in South Africa, with an efficacy of 55.4% among HIV-negative trial participants in a region where the vast majority of strains are B.1.351 variants. Across both trials, NVX-CoV2373 demonstrated 100% protection against severe disease, including all hospitalization and death.

Novavax. (Mar 11, 2021). Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials. Downloaded Mar 11 from https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and